Acute Lymphoblastic Leukemia Market Expected to Grow at a CAGR of 4.8% During the Study Period of 2017-30 in 7 Major Markets

– “The growth of the ALL market is expected to be driven by the increase in incident cases of ALL, the constant adoption of approved and emerging therapies as well as an expected increase in investments in R&D activities. Cell therapies CAR- T is expected to dominate the acute lymphoblastic leukemia market, as five of the current immunotherapies are set to enter the market by 2023. “

LAS VEGAS, June 25, 2020 / PRNewswire / – DelveInsight announced the extension of the forecast period to 2020-2030 for its report on ‘Acute Lymphoblastic Leukemia (ALL) Market Overview, Epidemiology and Market Forecast -2030 ‘.

Findings of the report

  • B-cell lymphoblastic leukemia accounted for the majority of cases, or 82% of total ALL cases, compared to T-cell lymphoblastic leukemia.
  • United States accounted for the largest size of the acute lymphoblastic leukemia market, followed by Germany and France among the 7MM countries.
  • The main pharmaceutical and biotechnology companies investing in the ALL market are Gilead Sciences, Servier / Allogene, Bristol-Myers Squibb, AbbVie / Roche, Jazz Pharmaceuticals, Janssen Research & Development, AbbVie, Autolus Limited, Precision BioSciences / Servier and others.

Request free samples of report pages: https://www.delveinsight.com/sample-request/acute-lymphoblastic-leukemia-all-market

Acute lymphoblastic leukemia (ALL), also known as acute lymphoblastic leukemia, is a type of cancer that affects the blood and bone marrow. The tumor starts from young white blood cells called lymphocytes in the bone marrow; characterized primarily by the production of immature white blood cells, called lymphoblasts or excess leukemic blasts. ALL is caused by a lack of normal circulating blood cells. The exact causes of acute lymphoid leukemia remain mostly unknown; still, it is believed to result from mutations in one or more of the genes which usually control the development of blood cells. This mutation will cause abnormal growth. It is mainly classified into B cells and ALL T cells. ALL can occur at any age, but it’s more common in young children (0-14 years old) and it develops quickly, so people are usually only sick for a short time before being diagnosed.

Acute lymphoblastic leukemia, a rare blood cancer, had a total incidence of 10,341 within 7MM in 2017. The incidence of ALL is expected to increase further over the forecast period 2020-2030. The United States accounted for approximately 50% of the total acute lymphoid leukemia incident population in 7MM. Among the EU5 countries, Germany at the top of the list of the highest ALL incident cases, with France follow behind. Spain accounted for the lowest incidence of ALL among all 7MM countries.

The epidemiological analysis of acute lymphoblastic leukemia demonstrated a higher male preponderance, and approximately 56% of the affected population was in the

The DelveInsight Acute Lymphoid Leukemia Epidemiologic Segment of the Report provides historical and forecast trends for the period 2020-30 by forking the patient group into

  • Total incident leukemia cases,
  • Total incident cases of ALL,
  • Gender-specific ALL cases,
  • Diagnosed cases of ALL by age,
  • Specific cases of subtype of ALL,
  • Cases of ALL specific to a genetic mutation, and
  • Total number of cases treated from ALL

Acute Lymphoblastic Leukemia Market

Treatment options for acute lymphoid leukemia include chemotherapy, post-remission therapy (consolidation and maintenance therapy), targeted therapy, immunotherapy, and CAR-T cell therapy. Stem cell transplantation is also an alternative for patients who are in the early stages of treatment with high risk subtypes of ALL.

However, immunotherapy offers a broad and promising approach to curing cancer using the body’s immune system. Following the very first FDA approval for CAR-T Kymriah cell therapy (Tisangenlecleucel; Novartis) for the treatment of ALL, several advances in the clinical setting were made, leading to more effective treatment strategies. From 2020, targeted immunotherapy drugs are available to treat relapsed or refractory acute lymphoblastic leukemia cases and are a favorable option for the treatment of elderly patients in clinical practice. However, there is a significant need to develop appropriate strategies for adolescents and young adults with ALL, which fall between the standard categories of pediatric or adult ALL.

Acute lymphoblastic leukemia Marketed therapies

  • Asparlas: Pharmaceutical Servier
  • Blincyto (blinatumomab / MT 103): Amgen
  • Kymriah (tisagenlecleucel): Novartis Pharmaceuticals
  • Besponsa (inotuzumabozogamicin): Pfizer
  • Erwinaze (asparaginase Erwinia chrysanthemi): Jazz Pharmaceuticals / Porton Biopharma Limited
  • Iclusig (ponatinib): Takeda (Ariad Pharmaceuticals)

The current acute lymphoid leukemia market scenario is enriched by several companies evaluating new drug molecules and targets, as well as finding ways to increase the effectiveness of existing treatment approaches for ALL. DelveInsight believes that Blincyto with its broader indication, approval will be at an advantage over other parameter ranges and should dominate the second line parameter as well. However, it would face stiff competition from Besponsa and Kymriah.

The acute lymphoid leukemia pipeline hosts CAR-T cell therapies including KTE-X19 (Gilead Sciences), AUTO1 (Autolus Limited), PBCAR0191 (Precision BioSciences / Servier), UCART19 (Servier / Allogene) and Lisocabtagene Maraleucel / JCAR017 ( Bristol-Myers Squibb) which are the major factors driving the Acute Lymphoblastic Leukemia market.

Acute lymphoid leukemia Pipeline therapies

  • KTE-X19 (Sciences of Gilead)
  • UCART19 (Servier / Allogene)
  • Lisocabtagene Maraleucel / JCAR017 (Bristol-Myers Squibb)
  • Venetoclax / Venclexta / ABT199 / RG7601 (AbbVie and Roche)
  • Recombinant JZP-458 / PF743 / Erwinia asparaginase (Jazz Pharmaceuticals)
  • Daratumumab (Janssen Research & Development)
  • Imbruvica / Ibrutinib {Pharmacycliques (an AbbVie company)}
  • AUTO1 (Autolus Limited)
  • PBCAR0191 (Precision BioSciences / Servier)

Global Acute Lymphoid Leukemia Market Dynamics is expected to change positively during the forecast period 2020-30 owing to the increase in the incidence of ALL, the improvement in the increase in the number of expenses of global health, a refocusing on targeted immunotherapies and increased interest from the main players in pharma and biotechnology. However, there are obstacles that are also expected to slow growth in ALL markets. Due to the fact that it is a rare cancer, it is difficult to recruit patients in clinical trials. In addition, the cost of immunotherapies has always been questioned because most of the time, they are unaffordable. The entry of generics such as Sprycel (dasatinib) is another drag on the growth rate of the acute lymphoblastic leukemia market.

Identify the key trends in the Acute Lymphoblastic Leukemia market: https://www.delveinsight.com/report-store/acute-lymphoblastic-leukemia-all-market

Scope of the report

  • Geography covered: 7 Major Markets – United States, UE5 (Germany, Spain, Italy, France, and the UK), and Japan
  • Study period: Historical analysis over 3 years and forecast over 11 years (2017-2030)
  • Market segmentation: by geography, by therapy, by line of therapy
  • Covered companies: Gilead Sciences, Servier / Allogene, Bristol-Myers Squibb, AbbVie / Roche, Jazz Pharmaceuticals, Janssen Research & Development, AbbVie, Autolus Limited, Precision BioSciences / Servier and others.
  • Analysis: Comparative and joint analysis of emerging therapies, attribute analysis
  • Case studies
  • Opinions of KOL
  • Analyst’s point of view

Reason for purchase

  • Tailor-made primary and secondary research
  • 24/7 customer service
  • Option to customize and personalize research reports as needed

Contents

1.

Key ideas

2.

Executive summary of acute lymphoblastic leukemia

3.

SWOT Analysis of Acute Lymphoid Leukemia

4.

Acute Lymphoid Leukemia Market Overview At A Glance

5.

Acute Lymphoid Leukemia: Background and Overview of the Disease

6.

Acute lymphoid leukemia Diagnosis

7.

Acute lymphoid leukemia Epidemiology and patient population

8.

United States Acute lymphoblastic leukemia Epidemiology

9.

EU-5 By country Acute lymphoblastic leukemia Epidemiology

ten.

Japan Acute lymphoid leukemia Epidemiology

11.

Current Practices for the Treatment of Acute Lymphoid Leukemia

12.

Acute lymphoblastic leukemia treatment algorithms

13.

Acute Lymphoblastic Leukemia Guideline

14.

Unmet Need in Acute Lymphoblastic Leukemia Market

15.

Acute lymphoblastic leukemia: patient journey

16.

Key endpoints in acute lymphoid leukemia clinical trials

17.

Acute lymphoblastic leukemia Marketed therapies

18.

Emerging treatments for acute lymphoblastic leukemia

19.

Joint analysis of acute lymphoid leukemia

20.

Acute lymphoid leukemia: seven major market analyzes

21.

7MM Acute Lymphoid Leukemia Market Size

22.

US Acute Lymphoid Leukemia Market Size

23.

EU-5 Acute Lymphoblastic Leukemia Market Size

24.

Japan Acute Lymphoid Leukemia Market Size

25.

Market Access and Reimbursement of Acute Lymphoblastic Leukemia Therapies

26.

Acute Lymphoblastic Leukemia Market Drivers

27.

Obstacles to the Acute Lymphoblastic Leukemia Market

28.

Annex

29.

Features of DelveInsight

30.

Disclaimer

31.

About DelveInsight

Request a WebEx presentation of the report: https://www.delveinsight.com/report-store/acute-lymphoblastic-leukemia-all-market

Associated reports

Acute Lymphoblastic Leukemia (ALL) – Pipeline Insights, 2020
Acute lymphoblastic leukemia pipeline The report from DelveInsight presents comprehensive information about the current clinical development scenario and growth prospects in the Acute Lymphoblastic Leukemia market. treatment guidelines.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) Market Overview and Forecast – 2030
DelveInsight’s “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia “provides an in-depth understanding of the use of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia as well as CAR T-Cell Therapy for Acute Lymphoblastic Leukemia market trends in 6MM, i.e. United States and UE5 (Germany, Spain, Italy, France and the UK).

About DelveInsight
DelveInsight is a leading business consultant and market research firm focused exclusively on the life sciences. It supports pharmaceutical companies by providing them with complete end-to-end solutions to improve their performance. Get hassle-free access to all healthcare and pharmaceutical market research reports through our PharmDelve subscription platform.

Contact us:

Shruti Thakur
[email protected]
+ 91-9650213330

SOURCE DelveInsight Business Research, LLP

Source link

About Annie Baxley

Check Also

Mold By-Product Causes Expanded Dog Food Recall – WHIO TV 7 and WHIO Radio

The United States Food and Drug Administration has extended a previously announced dog food recall …

Leave a Reply

Your email address will not be published. Required fields are marked *